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M protein is a fibrous, predominantly a-helical, coiled-coil molecule extending
from the cell surface ofgroup A streptococci (1, 2). Through its ability to allow
this organism to escape phagocytosis by the host's defenses, Mprotein acts as the
primary virulence factor for these streptococci. Protection from streptococcal
infection is due primarily to opsonization by type-specific antibodies directed
against the M protein (3).
Previously, serological crossreactions among purified M proteins of various
serotypes proved limited (4, 5), with restricted crossprotection in phagocytic
assays (5). These studies were confined, however, to fragments ofthe M protein
that represent approximately the amino terminal half of the native molecule,
distal to the streptococcal cell surface (6). Similar limited crossreactivity was seen
(7-9) with peptides synthesized on the basis of amino acid sequence determina-
tions within these amino terminal fragments. Opsonic antibodies in these studies,
however, were type-specific. Recently, a study (10) using mAbs directed against
the entire M6 protein suggested that the amino terminal region ofthe M protein
molecule was variable with respect to antigenic epitopes shared among M
serotypes. Conversely, more extensive crossreactions maybe reserved for regions
moreproximal to the cell surface (i. e., the carboxy terminal halfofthemolecule).
The mAb directed toward the amino terminal half of the M6 protein (10A11)
crossreacted with 5 different M serotyping strains, whereas the mAb directed
toward the carboxy terminal half (10136) did so with 20 of these serotyping
strains. Through the use of DNA probes, the location of the conserved epitope
was found (2) to be located more centrally in the native molecule, and just
carboxy terminal to the pepsin cleavage site, which divides the molecule approx-
imately in half. As a further definition of the antigenic structure of the M
molecule, Manjula et al. (11) identified regions within the amino terminal half
of the M5 and M6 proteins that crossreact, and they defined a hypervariable
antigenic domain located in the amino terminal quarter of these proteins. In a
more recent study using DNA probes of the M6 gene to identify constant and
variable regions of M proteins in other serotypes, it was found that the carboxy
terminal region ofthe Mprotein was conservedamong strains ofseveral different
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serotypes (12). The DNA sequence of the M6 molecule revealed the presence of
three distinct blocks of extensive sequence repeats. Two repeat blocks were in
the amino terminal half of the molecule (regions A and B) and one was carboxy
terminal to the pepsin cleavage site (region C) (13).
In this study, to determine the extent of crossreactivity of mAbs I OA 11 and
10136 and that of a newly isolated anti-M6 protein mAb, IOF5, we used clinical
isolates of group A streptococci representative of 58 M serotypes that had not
been passaged in the laboratory . To specifically define the epitopes on the M6
molecule for these crossreactive antibodies, purified M6 protein was selectively
cleaved with pepsin and staphylococcal V8 protease. Resultant peptides were
separated by HPLC and selected mAb-reactive peptides were subjected to amino
acid sequence analysis. Alignment of these amino acid sequences with the
complete DNA sequence for the M6 protein gene (13), in concert with selective
inhibition studies with synthetic peptides, revealed the location and amino acid
sequences of these crossreactive epitopes on the M6 protein .
Materials and Methods
Isolation and Purification of M Protein from Escherichia coli (ColiM6).
￿
M6 protein was
purified from E. coli containing plasmid pJRS42.13 bearing the structural gene for type
6 M protein (emm6; references 13, 14), as described by Fischetti et al (6).
Production and Purification of mAbs.
￿
mAbs IOAI I and IOB6 were prepared against
phage lysin-extracted M6 protein and purified from culture supernatants as previously
described (6). mAb 1OF5 was prepared against ColiM6 protein (above) using techniques
applied previously (6), with the exception that BALB/c x SJL/J (F, cross) were used for
the immunization and that SP2/O myeloma cells were used for the fusion. mAbs IOAI I
and IOB6 have been previously characterized (10) as having a variable epitope in the
amino half of the M6 protein and a conserved epitope near the center of this molecule,
respectively.
Bacterial Strains.
￿
Clinical isolates of group A streptococci, representing the various M
serotypes, were obtained from The Rockefeller University Culture Collection housed in
this laboratory. Strains selected were not passaged in the laboratory other than lyophili-
zation to preserve cultures. M serotypes and their respective strains were as follows: M 1,
D710; M2, D444; M3, D922; M4, D896; M5, 13788; M6, D471 ; M8, D784 ; M9, D339;
M11, A658; M12, A735; M13, D742 ; M14, D469; M15, D424; M17, 1GL 12 ; M18,
Bacterial Dot Blot Immunoassay.
￿
mAbs 1OA11, l OB6, and lOF5 were assayed for their
ability to react with the various representative M serotype strains using the bacterial dot
blot immunoassay. Briefly, overnight Todd-Hewitt brothcultures ofgroup A streptococcal
strains were washed twice with PBS, pH 7.4, containing 0.02% sodium azide. Washed
cells were then suspended to an OD of 0.5 at 650 nm (18-mm tube) and 25-t1 aliquots
were attached to a nitrocellulose sheet via suction through a dot-blotting manifold (Bio-
Rad Laboratories, Richmond, CA). Nitrocellulose sheets were allowed to air dry and were
blocked for a minimum of 2 h in PBS containing 0.5% Tween (PBS/Tween). Dot blots
were then processed with appropriate mAbs and alkaline phosphatase conjugate as per
immunoblots described by Fischetti et al. (6). Intensity of immunoreactive dots was
monitored by a reflectance densitometer with a 530 nm filter (Gilford Instrument
Laboratories, Inc., Oberlin, OH) interfaced with a 3390A integrator (Hewlett-Packard
1RP268; M19, 1GL205; M22, F312; M23, 1RP14; M24, 22RS72 ;
11RS100; M27, A910; M28, F416; M29, D470; M30, 1GL120;
M25,
M31,
D316; M26,
F376; M32,
IORS101 ; M33, A984; M36, A457 ; M37, D466; M38, 2RSC3; M39, D869; M40, D733 ;
M41, D463 ; M42, 1RS79; M43, 0506 ; M44, C848; M46, A837 ; M47, C716; M48, D493;
M49, D938; M50, A203 ; M51, A291 ; M52, A889 ; M53, D948; M54, D432; M55, D442;
M56, D633 ; M57, D306 ; M58, D998; M59, D465; M60, D398; M61, D812 ; M62, A956;
M63, A459; M65, A793; M66, A794 ; M67, D795.1228
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Co., Rockville, MD). Peak heights were adjusted with conjugate controls and ColiM6
protein standards.
Enzymatic Cleavage ofM Protein with Pepsin.
￿
-100 nmoles of ColiM6 (5.8 mg) lyophi-
lized from distilled water were dissolved in 0.98 ml of 100 mM sodium phosphate buffer,
pH 5.8. Pepsin (Worthington Biochemical Corp., Freehold, NJ) was added at a 1:20
(enzyme/substrate) ratio from a 2 mg/ml stock and the mixture was rotated at 37°C for
2 h. After this incubation, the digest was centrifuged at 12,800 g for 10 min and the
supernatant was frozen in aliquots at -70°C.
Enzymatic Cleavage with BacterialProtease.
￿
ColiM6 wascleaved at glutamic acid residues
by staphylococcal strain V8 protease (Worthington Biochemical Corp.), according to the
method of Drapeau (15). Cleavage was at an enzyme/substrate ratio of 1:100 in 50 mM
ammonium bicarbonate/2 mM EDTA for 12 h at room temperature. The reaction
mixture was then lyophilized in aliquots and stored at -70°C.
Blocking ofLysine Residues.
￿
Lysine residues were blocked by dihydroxypropylation of
the e-amino group of these residues according to the method of Acharya et al. (16).
Blocking ofArginine Residues.
￿
Arginine residues were blocked by treatment with 1,2-
cyclohexanedione according to the method of Patthy and Smith (17).
HPLC Separation ofPeptides.
￿
HPLC separations of peptides resulting from enzymatic
digestion of ColiM6 protein were performed on a Waters HPLC system (Waters Associ-
ates, Milford, MA). Linear acetonitrile gradients were run in 0.05% TFA at 1 ml/min on
either a Partisil PXS 10/25 ODS-2 (C18) column (Whatman Inc., Clifton, NJ) or an
Ultrapore RPSC (C3) column (Altex Scientific, Inc., Berkeley, CA). Elution of peptides
was monitored at 220 nm. Column fractions correspondingto reactive peaks were pooled
and taken to near dryness in a Speedvac (Savant Instruments, Inc., Hicksville, NY).
MolecularSize Determination ofIsolated Peptides.
￿
Relative molecular weights ofpeptides
isolated by HPLC were determined by 15% SDS-PAGE (18), followed by immunoblotting
on nitrocellulose (6) with their respective reactive mAbs. Based on the migration of
molecular weight standards (phosphorylase b, 94,000; BSA, 67,000; OVA, 43,000;
carbonic anhydrase, 30,000; soybean trypsin inhibitor, 20,100; a-lactalbumin, 14,400),
the apparent molecular weights ofthepeptides of interest detectable by this method were :
N-PD15,
￿
9,500; N-PD22,
￿
9,200; N-PD29, ^-10,000 (data not shown).
ELISA.
￿
ELISA of the peptides separated by HPLC wasperformed as follows: Aliquots
(10-50 Al) were taken from fractions representing absorbance peaks on the HPLC
chromatograph and were dried onto 96-well plates (Immulon 11; Dynatech Laboratories,
Inc., Alexandria, VA) overnight at 37°C under vacuum. Carbonate buffer (0.05 M
Na2CO3/NaHCO3, pH 10, 100,ul) was added to each well and incubated at 37°C for 2
h. Plates were then washed and processed with appropriate antibodies and alkaline
phosphatase conjugate according to Fischetti's modification (19) of the method of EngvalI
and Perlmann (20). After the finalwash, immunoreactivity was visualized with theaddition
of 200 A,1 of 1 mg/ml p-nitrophenyl phosphate (Sigma Chemical Co., St. Louis, MO) in
10% diethanolamine containing 1 MM MgC12, pH 10. Plates were read in an Elida-5
ELISA plate reader (Physica, Inc., New York) at 405 nm.
ELISA of crude enzymatic digests or selectively blocked peptides was performed by
diluting the respective Preparations in carbonate buffer, adding 100 J1 per well on a 96-
well plate, and incubating them overnightat 4°C. Plates were then washed and processed
as above.
Competition ELISA. For competition ELISA, wells were coated with 100 Al of 100
ng/ml solution of ColiM6 in PBS, pH 7.4, 18 h at 37°C. Optimal mAb dilutions were
determined by titration vs. ColiM6. Competing peptides were mixed with the optimal
antibody dilution in PBS containing 0.05% Brij 35, pH 7.4, (PBS/Brij) at decreasing
molar excesses relative to the ColiM6, starting with 2000x molar excess. Peptide-mAb
mixtures were rotated 18 h at 4°C and 100 tel of each were added per well of a ColiM6
protein-sensitized, PBS/Brij-washed plate and incubated for 3 h at 37°C. Plates were
then washed and processed as above and percent inhibition was determined.
Amino Acid Sequence Analysis.
￿
Amino acid sequence analyses were performed on 5-10
nmol peptide samples by an automated Edman degradation method at The RockefellerTABLE I
Group A Streptococcal MSerotypes Reactive with M6 Protein mAbs
10A11, 10B6, and 10175, as Determined by Bacterial
Dot Blot Immunoassay
JONES ET AL.
Monoclonal antibody
Results
Strains listed are those above the lower limit for positive reactions. A
densitometer reading of 105 peak height units (1 peak height unit =
1.25 X 10-4 mV) above conjugate control values (just visible to the
nakedeye) was taken as the cutoff point.
* M serotypes of clinically isolated strains, as determined by M type-
specific antiserum.
Underlined M serotypes(below mAbs 10136 and lOF5) were positive for
their respective mAbs alone, whereas those M serotypes not underlined
were positive for both lOB6 and lOF5.
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University Protein Sequencing Facility on a gas phase sequence analyzer (Applied Biosys-
tems, Inc., Foster City, CA).
Synthesis of Peptides.
￿
Synthetic peptides were prepared according to the solid-phase
method of Barany and Merrifield (21) and were purified by HPLC. Sequences were
verified by amino acid sequence analysis (see above).
Crossreactions ofmAbs with M Serotypes.
￿
The reactivity of mAbs IOA11, 10136,
and 1OF5 with nonpassaged clinical isolates representing each of 58 M serotypes
was monitored using the bacterial dot blot immunoassay. Table I shows the
crossreactions determined by reading the processed dot blots with a densitome-
ter; values >10' densitometric units were considered positive. Using this crite-
rion, mAb 10A11 was crossreactive with 9 different non-M6 serotypes, 10136
with 30, and 1OF5 with 30 . However, the same 30 strains were not recognized
by both mAbs l OB6 and lOF5. Together, these two antibodies recognized 39 of
the 58 M serotypes examined (67%).
IsolationofReactive, Pepsin-derived Peptides.
￿
The strategy used for the isolation
of reactive peptides to mAbs recognizing variable (IOA11) and conserved (10136
and 1OF5) epitopes was to cleave the ColiM6 protein with pepsin to separate
these epitopes into different M protein fragments. After this cleavage, the
peptides were separated by reverse-phase HPLC on a C3 column (Fig. IA).
Elution fractions containing peptide peaks were subsequently dried onto micro-
titer plates and processed by ELISA with the lOA 11, 1OB6, and lOF5 mAbs.
l0AII 10W 1OF5$
M5,* M6, M14 Ml, M3, M4 M1, M2, M3
M27, M29, M32 M5, M6, M12 M4, M5, M6
M37, M53, M57 M14, M18, _M22 M8, M12, M14
M58 M23, _M24, M26 M17, M18, M19
M27, M29, M30 M23, M26, M27
M32, _M36, M38 _M28, M29, M30
_M41, M43, M44 M32, M33, M37
_M46, M48, _M50 M38, M39, M43
_M52, M53, M55 M44, M48, M53
M56, M57, _M58 _M54, M55, M56
M62 M571230
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FIGURE 1 .
￿
Reverse-phase HPLC of a pepsin digest of ColiM6 protein on a C3 column. (A)
Separation of the crudepepsin digest; 15-40% linear acetonitrile (ACN)gradient at I ml/min
(150 min). (B) Rechromatography of pepsin fragments N-PD15 and N-PD22; gradient as in
(A). (C) Rechromatography of pepsin fragment N-PD29; 15-30% linear ACN gradient at I
ml/min (130 min), isocratic at 30% (30 min).
Several peptide peaks were reactive with these antibodies, but three native (N)'
peptides (N-PD15, N-PD22, and N-PD29) were selected for further purification
and study due to their relative reactivity and isolated position on the chromato-
gram with respect to otherpeaks. The three peptides were repurified by pooling
fractions corresponding to the reactive peaks and rechromatographing on the
C3 HPLC column (Fig. 1 B and C). The ELISA readings on the purified peptides
(Table II) show that peptide N-PD29 reacted with mAb l OA11, while N-PD15
and N-PD22 reacted with mAbs IOB6 and IOF5.
Amino Acid Sequence Analysis and Location of Reactive Pepsin-derived Pep-
tides. Peptides N-PD15, N-PD22, and N-PD29 were subjected to partial amino
acid sequence analysis with the resultant sequences presented in Fig. 2. Based on
the observed sequence, peptides were positioned within the M6 molecule by
alignment with the amino acid sequence predicted from the DNA sequence for
emm6, described by Hollingshead et al. (13). Fig. 3 shows the alignment of the
10A11+ N-PD29 peptide in the amino terminal half of the native M molecule,
as expected (10). 1OB6+ and IOF5' peptides N-PD15 and N-PD22 overlap in
the carboxy terminal half ofthe protein.
Identification of the 10AII Epitope.
￿
On the basis of the amino acid sequence
of peptide N-PD29 isolated from the ColiM6 protein and its position on the M6
' Abbreviations used in this paper:
￿
ACN, acetonitrile; CHD, 1,2-cyclohexanedione; DHP, dihy-
droxypropylation ; N, native; S, synthetic.
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TABLE 11
Reactivity ofPurified Peptides Isolated from Native M6 Protein with
mAbs 10A11, 10B6, and IOF5, as Determined by ELISA
134
￿
140
￿
145
S-M6/ Lys-Ile-Ala-Lys-Olu-Gin-Glu-Ser-Lye-Glu-Thr-Ile-Cye
134-145 (--------- Repeats at 159-170, 184-195 ---------)
* Absorbance readings at 405 nm after 30 min incubation in substrate.
$ Dihydroxypropylated N-V8-1 peptide.
4N-V8-1 peptide treated with 1,2-cyclohexanedione.
124
￿
130
￿
135
￿
140
￿
145
￿
150
N-PD29 Lys-Lys-Thr-Leu-Aep-Glu-Thr-Val-Lye-Asp-Lye-Ile-Ala-Lys-Glu-Gln-Glu-Ser-Lye-Glu-Thr-Ile-Gly-Thr-Leu-Lye-Lys-Thr-Leu-_-- _______-_________________________ Repeats at 149-173, 174-198 __________-__________________-___-_)
(________ Repeats at 202-211 _______)
228
￿
235
￿
240
￿
245
￿
250
N-PD15 Ala-Lys-Lys-Aap-Glu-Gly-Asn-Lys-Val-Ber-Glu-Ala-Ser-Arg-Lye-Gly-Leu-Arg-Arg-Asp-Leu-Aep-Ala-3er-Arg-Glu----
(__________-___ Repeats at 285-302 -------------
265
￿
270
￿
275
￿
280
￿
285
￿
290
N-PD22 Leu-Thr-Ala-Glu-Leu-Aap-Lye-Val-Lys-Glu-Glu-Lys-Gln-Ile-Ser-Aep-Ala-Ser-Arq-Gln-Gly-Leu-Arq-Arg-Aep-Leu----
(239-Rep-241)
￿
(-- Repeats at 243-248 -----
275
￿
280
￿
285
￿
290
￿
295
N-V8-1 Glu-Lys-Gln-Ile-Ser-Aep-Ala-Ser-Arg-Gln-Gly-Leu-Arg-Arq-Asp-Leu-Aap-Ala-Ser-Arg-Glu
(239-Rep-241)
￿
(------------ Repeats at 243-254 --_______-_)
140
￿
145
￿
150
￿
155
S-M6/ Glu-Ser-Lys-Glu-Thr-IIe-Gly-Thr-Leu-Lys-Lye-Thr-Leu-Aep-Glu-Thr-Val-Lys-Asp-Cya
140-158 (-__-------- Repeats at 165-183 ___________________________)
(------------ Repeats at 190-200 -----------)
￿
(---- Repeats at 202-208 ---)
248
￿
255
￿
260
￿
265
S-M6/ Cye-Leu-Aep-Ala-Ber-Arg-Glu-Ale-Lys-Lye-Gln-Val-Glu-Lys-Asp-Leu-Ala-Asn-Leu-Thr-Ala-Glu-Leu 248-269
￿
(---------------- Repeats at 290-302 ---------------)
FIGURE 2.
￿
Amino acid sequences of reactive peptides isolated from the native M6 protein
andsyntheticpeptides. Synthetic peptides were prepared with cysteines (Cye) forusein coupling
to acarrier protein. PD, peptide derivedfrom pepsin digestionof ColiM6; V8, peptide derived
from V8 protease digestion of ColiM6.
molecule, two peptides were synthesized to aid in locating the epitope site for
mAb I OA 11 . Fig. 2 lists the amino acid sequence of these synthetic peptides and
Fig. 3 lists their position relative to the native peptide and the entire M6 molecule.
Both native and synthetic peptides were used in competition ELISA's to compete
for the ability of these mAbs to react with the entire M6 protein.
Fig. 4A illustrates the competitive inhibition of the binding of monoclonal
10A11 to ColiM6 by peptide N-PD29 and synthetic (S) peptides S-M6/134-145
and S-M6/140-158 . As expected, peptide N-PD29 inhibited nearly 100% of this
reaction. In addition, peptide S-M6/134-145 also inhibited this reaction, nar-
rowing the epitope site for this antibody to residues 134-145, which are repeated
Peptide
10A11
Monoclonal antibody
10136 10F5
N-PD15 <0 .100* >2 .0 >2.0
N-PD22 <0.100 >2 .0 0.602
N-PD29 1.696 <0 .100 <0.100
N-V8-1 <0.100 >2 .0 >2 .0
N-V8-1/DHP* ND 0.120 1.129
N-V8-1/CHDI ND 0.214 1.3051232
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￿
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N-PD29 =
￿
-------- -------N-PD15
S-M6/134-145 "+
￿
-------- N-PD22
S-M6/140-158 "-+
￿
"--~ N-V8-1
"--+ S-M6/248-269
(-)290-302*
10A11 Epitope -
￿
-
￿
-
￿
- 1OB6 a IOF5 Epitope Site
FIGURE 3.
￿
Position of native (N) and synthesized (S) peptides within entire M6 molecule.
Amino acid sequence of M6 protein determined from the nucleotide sequence of the M6
protein gene. A, B, and C represent regions of sequence homology within the M6 sequence.
(0--9) Sequence verified by amino acid sequence determination; (0---I") inferred from
DNA sequence. PD, peptide derived from pepsin digestion of ColiM6; V8, peptide derived
from V8 protease digestion of ColiM6. Asterisk indicates that residues 290-302are an amino
acid sequence repeat of residues 248-260 located in syntheticpeptideS-M6/248-269.
at positions 159-170 and 184-195 within the M6 molecule. On the other hand,
peptide S-M6/140-158, which overlaps S-M6/134-145 at residues 140-145, did
not inhibit this reaction, thus defining the lOA 11 epitope as the hexapeptide
sequence comprising residues 134-139 (Lys-Ile-Ala-Lys-Glu-Gin). This sequence
is repeated at residues 159-164 and 184-189 within the B repeat region of the
M6 molecule (13).
Identification of the 10B6 Epitope: Isolation of Reactive, V8 Protease-cleaved Pep-
tides. Since pepsin-derived, IOB6-reactive peptides N-PD 15 and N-PD22 over-
lap, we attempted to find a smaller, reactive peptide in the region they share.
We found several glutamic acid residues within the regions covered by these
peptides. Therefore, staphylococcal V8 protease was selected to cleave ColiM6
at these amino acids. The peptides in the V8 protease digest of ColiM6 were
separated on a C3 reverse-phase HPLC column (Fig. 5) . Only one peak reacted
with mAb lOB6 and none reacted with mAb l0A 11 . The lOB6+ fractions were
pooled and rechromatographed on a C18 reverse-phase HPLC column (Fig. 5,
inset). Only one of the resultant peaks was reactive with lOB6 on ELISA (Table
11) and was designated N-V8-1 . This peptide was sequenced in its entirety (Fig.
2) and found to correspond to the 21 residues at positions 275-295 in the native
M6 molecule (Fig. 3).
Fig. 4B illustrates the competitive inhibition of 1OB6 binding to ColiM6 by
peptides N-PD 15, N-PD22, and N-V8-1 and S-M6/248-269. Peptides N-PD 15,
N-PD22, and N-V8-1 inhibit the reaction, as expected. This placed the epitope
site for mAb 10B6 in the 21-residue span of peptide N-V8-1, 275-295. The first
13 amino acids of synthetic peptide S-M6/248-269 repeat at residues 290-302.
This sequence repeat overlaps peptide N-V8-1 at residues 290-295. Since this
synthetic peptide and, by inference, its sequence repeat did not appreciably
inhibit the reaction of mAb 10B6 with N-V8-1, the 10B6 epitope was thereby
narrowed to residues 275-289. A portion of this sequence (281-289) is repeated
at residues 239-247, with an amino acid substitution (lysine for glutamine) at
residue 242, which may represent a repeat of this epitope site (Fig. 2).
Dihydroxypropylation (DHP) ofPeptide N-V8-1.
￿
To further define the position
of the lOB6 epitope within the 15 residue span (275-289), the 4E-amino group of0
n c
c
0
n
L
C
Molar Excess of Peptide
2.10' 103 10 2 10 1 IOa 10-1
10-1 (:F3 10-4
C
￿
Molar Excess of Peptide
100
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IOF5 Monoclonal
x -N-PDI5
s -N-PD22
o -5-M6/248-269
v -N-V8-I
0
2x103 103 102 10 1 IOa 10' 102 103 10 +
Molar Excess of Peptide
FIGURE 4.
￿
Competition ELISAs with N and S peptides vs . ColiM6 . Percent inhibition of
binding of mAbs IOA1 I (A), 10136 (B), and IOF5 (C) to ColiM6 protein by decreasing molar
excesses of the various peptides .
the sole lysine in the N-V8-1 peptide, located at residue 276, was blocked by
dihydroxypropylation . This treatment almost totally removed the ability of
peptide N-V8-1 to react with mAb 1OB6 (Table II), suggesting that the amino
terminal end of this peptide was involved in antibody binding .
Treatment ofPeptideN-V8-1 with 1,2-Cyclohexanedione (CHD).
￿
To delineate the
binding site of mAb 1OB6 still further, the arginines in peptide N-V8-1 at
residues 283, 287, 288, and 294 were blocked with 1,2-cyclohexanedione . As
was the case for DHP treatment of this peptide, CHD treatment almost entirely
eliminated reactivity with the 1OB6 mAb (Table II), thus suggesting that these
arginine residues may also be part of the 1OB6 epitope .
Identification of the 10F5 Epitope .
￿
Since mAb 1OF5 showed similar reactivity
to the pepsin-derived peptides N-PD15 and N-PD22 as mAb 1OB6, a similar
approach to the definition of its epitope on the M6 protein was taken . mAb1234
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FIGURE 5.
￿
(A) Reverse-phase HPLC of VS protease digest of ColiM6 protein. Separation of
crude V8 protease digest; 5-40% linear ACNgradient at I ml/min (120 min) on a C3 column.
(B) Rechromatography of N-V8-1 peptide; 5-40% linear ACNgradient at 1 ml/min (150 min)
on a C18 column.
IOF5 reacted strongly with the V8 protease-derived peptide N-V8-1 (Table II),
indicating that its epitope was also located somewhere within this 21 residue
peptide. Competition ELISA with native peptides N-PD15, N-PD22, and N-V8-
1 and synthetic peptide S-M6/248-269 (Fig. 4C) showed similar results for mAb
I OF5 as for 10116 (Fig. 4B). The lack of competition by peptide S-M6/248-269
narrowed the epitope site for mAb IOF5 to the sequence of 15 residues (275-
289) that also contains the 10116 epitope. As was the case for 10116, the 1OF5
epitope may be repeated at residues 239-247.
Blocking experiments on peptide N-V8-1, including DHP treatment of the
lysine residue at position 276 and CHD treatment of the arginines at positions
283, 287, 288, and 294 (Table II), showed some diminution of the reactivity of
mAb IOF5 for this peptide, although not to the extent as that experienced for
mAb 10116.
The immunological diversity of the group A streptococci is shown by the
immunospecificity of the large number of M protein serotypes within these
organisms (3). Crossreactions seen among M serotypes have been limited due to
the fact that previous researchers confined their studies to the N-terminal half
of the molecule (4, 5). One mAb prepared against the entire M6 protein, IOA 11,
which showed limited crossreactivity, also bound to the amino terminal half of
this molecule (10), distal to the cell surface (6). Another mAb generated against
this protein, 10116, showed greater crossreactivity with other M serotypes than
had previously been experienced, and bound a region near the center of this
molecule (10), more proximal to the cell surface.
In the current study, mAbs IOA 11 and IOB6, as well as an additional mAb,
1OF5, were reacted with clinical strains representing 58 M serotypes that had
not been passaged in the laboratory. mAb IOA 1 I crossreacted with nine non-
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M6 strains, an increase offour compared with crossreactions cited in the previous
study (10), in which laboratory passaged strains were used. mAbs IOB6 and IOF5
proved to be highly crossreactive, each binding to 30 non-M6 strains, an increase
of 10 for mAb 1OB6, where clinical isolates were used. This difference may
indicate either that laboratory passage reduces the amount ofMprotein present
on the surface of these strains or that the bacterial dot blot immunoassay is more
sensitive than the colony blot immunoassay used previously (10).
The site for the IOA11 epitope, in the relatively variable amino terminal half
of the M6 molecule, was determined to be the six-amino-acid sequence compris-
ing residues 134-139 on the M6 protein (Lys-Ile-Ala-Lys-Glu-Gln) . This epitope
is repeated twice at residues 159-164 and 184-189, within the B repeat region
ofthe molecule (Fig. 3) (13). The 10A11 mAb crossreactvd with nine non-type
M6 strains including the M5 typing strain T5B/126/3 (10) and the M5 nonpas-
saged strain, B788. Manjula etal. (22) have sequencedthe entire pepM5 fragment
of strain B788. Amino acid residues 154-159 of this pepM5 sequence, in an «-
helical region of the molecule (23), are identical to residues 134-139, 159-164,
and 184-189 of ColiM6, making up the IOA11 epitopes, and are likely respon-
sible for the crossreactivity seen between these two serotypes with this antibody.
Both mAbs 1OB6 and 1OF5 had their epitope sites identified as the 15-amino-
acid residue sequence 275-289 (Glu-Lys-Gln-Ile-Ser-Asp-Ala-Ser-Arg-Gln-Gly-
Leu-Arg-Arg-Asp), overlapping the C repeat region in the carboxy terminal half
of the molecule (Fig. 3). This sequence is partially repeated at residues 239-247,
with an amino acid substitution at residue 242, suggesting that one or both of
these epitopes may be repeated. The fact that DHP of the sole lysine located at
residue 276 of the N-V8-1 peptide blocked this peptide's ability to react with
monoclonal IOB6, suggests that this lysine and the amino terminal region ofthis
peptide are involved in this determinant. However, the possibility that blocking
the E-amino group of the lysine resulted in a conformational change in the
peptide, thus altering an epitope at another site within the peptide, cannot be
ruled out. The same is also true with regard to the blocking of the arginines at
residues 283, 287, 288, and 294 in the N-V8-1 peptide. Since blocking these
lysine and arginine residues had a much less profound effect on the binding of
IOF5, these residues may be at the fringes of the 10F5 epitope, which may be
centered between them (i. e., residues 277-282). The differential effect of
arginine and lysine blocking on binding of 1OB6 and 1OF5 makes it apparent
that these two mAbs bind to two distinct sites within the same 15-amino-acid
sequence. This is borne out by the differences in the M serotypes with which
each mAb crossreacts. Despite the fact that mAbs IOB6 and IOF5 each recognize
30 different M serotypes of streptococci, they do not recognize the same strains
in all cases. Combined, 39 ofthe 58 group Astreptococci M serotypes examined
may be identified with these two monoclonals.
Chou-Fasman analysis of the ColiM6 amino acid sequence (V. A. Fischetti, K.
F.Jones, S. K. Hollingshead, andJ. R. Scott, manuscript in preparation) reveals
that the epitopes for mAbs IOA11, 1OB6, and IOF5 are in predominantly «-
helical regions of the M6 protein. The sequence for the IOAI 1 epitope (residues
134-139) repeats at residues 159-164 and 184-189, which are also contained1236
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within a large a-helical region and thus, are likely to serve as additional epitopes
for this antibody.
The epitope site for 10136 and 105, however, contains an additional feature,
in that the region encompassing residues 282-285 within the 15 residue site
shows some (3 turn potential due to the helix breaking potential of the glycine at
position 285. This possible disruption of the helix may be partly responsible for
the immunogenicity of this particular site on the molecule, by better exposing
this area on the surface of the M protein fiber.
mAbs 10136 and IOF5 each crossreacted with 30 different M serotypes, only
two of which, type 5 and type 24, have had their M proteins sequenced to any
degree (7, 22, 24). These sequences, however, are incomplete with respect to
the entire M molecule, since they deal only with amino terminal fragments
derived from pepsin digestion, and therefore no sequences corresponding to the
10136 and I OF5 epitopes are currently available.
This study has shown that the epitopes for mAbs 10136 and 101`5 are located
centrally within the M6 protein, yet are still accessible to antibody binding on
intact streptococcal cells. In spite of this accessibility and the fact that 10136 and
101`5 are of IgG subclasses that should fix complement (IgG2a and IgG2b,
respectively), these mAbs, as well as IOA 11 (IgG 1), were not opsonic in phago-
cytic assays (K. F. Jones, S. A. Khan, B. W. Erickson, S. K. Hollingshead, J. R.
Scott, and V. A. Fischetti, manuscript in preparation). Whether the lack of
function of these antibodies is due to the location of their epitopes on the
molecule or their complement fixing capabilities is currently under investigation.
Epitopes located more proximal to the cell wall may be shared by a greater
number of groupA streptococal M serotypes, as suggested by DNA hybridization
experiments (12). However, whether theseepitopes are also accessible to antibody
binding on the cell surface or capable of eliciting opsonic antibodies must await
further studies. It is hoped that the identification of these and other epitopes
shared by many of the group A streptococcal M serotypes may form the basis
for synthetic vaccines that can elicit crossprotective antibodies against multiple
M serotype infection or that can be used as reagents for the identification of M
protein-containing streptococci .
Summary
mAbs IOA 11, 10136, and IOF5, raised against the native group A streptococcal
M6 protein, were examined for their crossreactivity with non-laboratory pas-
saged clinical isolates, representing 58 M serotypes, by bacterial dot blot immu-
noassay. mAb IOAI I crossreacted with 9, mAb 10136 with 30, and mAb IOF5
with 30 different non-M6 serotypes. To identify the epitopes for these antibodies,
the native M6 protein was cleaved with pepsin or staphylococcal V8 protease.
Resultantpeptides were purified by HPLC, examined for bindingto crossreactive
mAbs in ELISA, and reactive peptides were subjected to amino acid sequence
analysis. Peptides were aligned with the amino acid sequence of the entire M6
protein predicted by the DNA sequence of the M6 gene. Competitive inhibition
studies using peptides synthesized on the basis of peptide and DNA sequences,
in concert with selective blocking of amino acid residues, allowed for the further
identification and placement of these crossreactive epitopes within the M6JONES ET AL.
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molecule. The l 0A 11 epitope was located within the six amino acid residues at
position 134-139, which repeat at positions 159-164 and 184-189 within the
variable amino terminal half of the native molecule. The conserved 10136 and
l OF5 epitopes were positioned within a 15-amino-acid span at position 275-289,
with the possibility that either epitope could have been repeated at residues 239-
247 . Chemical modification of amino acids within this sequence aided in the
differentiation of these two epitopes. Such studies should aid in the recognition
of a sequence(s) common to a greater number of M serotypes, which may be
useful for future vaccine development or group A streptococcal identification.
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